Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total Revenue	$ 5,606,914	$ 2,965,171
Operating Expenses
Cost of Sales	3,697,854	2,383,703
General and Administrative	2,312,505	1,001,850
Inventory Written Off		2,009
Total Operating Expenses	6,010,359	3,387,562
Operating Losses From Operations	(403,445)	(422,391)
Other Income (Expense)
Interest Income	30,632	19,415
Interest Expense	(53,582)	(60,931)
Foreign Exchange Transaction Gain	1,462,697	2,260,482
Unrealized (Loss) Gain on Securities Investment	(9,535,009)	458,422
Realized Loss on Securities Investment	(258,245)
Loss on Investment on Security by Equity Method	(24,847)	458,422
Finance Costs	(582,868)	(4,903)
Other Income	11,256	5,471
Total Other (Expense) Income, Net	(8,949,966)	2,677,956
Net (Loss) Income Before Income Taxes	(9,353,411)	2,255,565
Income Tax	(451,337)
Net (Loss) Income	(9,804,748)	2,255,565
Net (Loss) Income Attributable to Non-Controlling Interest	(3,569,112)	636,703
Net (Loss) Income Attributable to Common Stockholders	(6,235,636)	1,618,862
Other Comprehensive Loss, Net
Unrealized Loss on Securities Investment	(1,987)	(12,599)
Foreign Currency Translation Adjustment	(1,769,440)	(1,674,021)
Comprehensive (Loss) Income	(11,576,175)	568,945
Comprehensive (Loss) Income Attributable to Non-controlling Interests	(4,328,924)	53,133
Comprehensive (Loss) Income Attributable to Common Stockholders	$ (7,247,251)	$ 515,812
Net (Loss) Income Per Share - Basic and Diluted	$ (0.73)	$ 0.16
Weighted Average Common Shares Outstanding - Basic and Diluted	8,572,222	10,001,000
Property Sales [Member]
Revenue
Total Revenue	$ 3,894,131	$ 2,954,389
Biohealth Product Sales [Member]
Revenue
Total Revenue	$ 1,712,783	$ 10,782